Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions

Trends in Pharmacological Sciences

Volumn 31, Issue 8, 2010, Pages 351-355

  Ito, Kiyomi ^a   Sugiyama, Yuichi ^b  

^a MUSASHINO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; SULFAPHENAZOLE; TOLBUTAMIDE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TRANSPORT; ENZYME INACTIVATION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AREA UNDER CURVE; BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 77955272644     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.05.002     Document Type: Article

References (36)

1. Ito K., et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 1998, 50:387-412.
2. Tucker G.T., et al. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Br. J. Clin. Pharmacol. 2001, 52:107-117.
3. Yao C., Levy R.H. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J. Pharm. Sci. 2002, 91:1923-1935.
4. Houston J.B., Galetin A. In vitro techniques to study drug-drug interactions of drug metabolism: cytochrome p450. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 169-215. Springer. K.S. Pang (Ed.).
5. Rostami-Hodjegan A. Translation of in vitro metabolic data to predict in vivo drug-drug interactions: IVIVE and modeling and simulations. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 317-341. Springer. K.S. Pang (Ed.).
6. Silverman R.B. Mechanism-based enzyme inactivators. Methods Enzymol. 1995, 249:240-283.
7. Rowland M., Matin S.B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1973, 1:553-567.
8. Ito K., et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. AAPS PharmSci. 2002, 4:E25.
9. Ito K., et al. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol. 2004, 57:473-486.
10. International Transporter Consortium Membrane transporters in drug development (Report from the FDA Critical Path Workshop). Nat. Rev. Drug Discov. 2010, 9:215-236.
11. Ito K., et al. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos. 2005, 33:837-844.
12. Brown H.S., et al. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. 2005, 60:508-518.
13. Zhang H., et al. Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin. Drug Metab. Toxicol. 2007, 3:667-687.
14. Galetin A., et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug Metab. 2007, 8:685-693.
15. Yeung C.K., et al. Drug disposition and drug-drug interactions: importance of first-pass metabolism in gut and liver. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 415-435. Springer. K.S. Pang (Ed.).
16. Galetin A., et al. Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab. Pharmacokinet. 2010, 25:28-47.
17. Obach R.S., et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 2006, 316:336-348.
18. Ohno Y., et al. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin. Pharmacokinet. 2007, 46:681-696.
19. Hisaka A., et al. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol. Ther. 2010, 125:230-248.
20. Kanamitsu S., et al. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 2000, 17:336-343.
21. Kato M., et al. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 2008, 25:1891-1901.
22. Kato M., et al. Extrapolation of in vitro metabolic and P-glycoprotein-mediated transport data to in vivo by modeling and simulations. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 299-315. Springer. K.S. Pang (Ed.).
23. Venkatakrishnan K., et al. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 2007, 37:1225-1256.
24. Obach R.S., et al. Inactivation of human cytochrome P450 enzymes and drug-drug interactions. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 473-495. Springer. K.S. Pang (Ed.).
25. Ito K., et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos. 2003, 31:945-954.
26. Mayhew B.S., et al. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 2000, 28:1031-1037.
27. Obach R.S., et al. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35:246-255.
28. Fahmi O.A., et al. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos. 2008, 36:1698-1708.
29. Rowland-Yeo K., et al. Physiologically based mechanistic modeling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 2009, 39:298-309.
30. Isoherranen N., et al. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem. Res. Toxicol. 2009, 22:294-298.
31. Jamei M., et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 2009, 24:53-75.
32. Shitara Y., et al. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 2005, 45:689-723.
33. Zhang L., et al. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008, 38:709-724.
34. Unadkat J.D., et al. The impact and in vitro to in vivo prediction of transporter-based drug-drug interactions in humans. Enzyme- and Transporter-Based Drug-Drug Interactions 2010, 517-553. Springer. K.S. Pang (Ed.).
35. Shitara Y., et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 2003, 304:610-616.
36. Watanabe T., et al. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 2009, 328:652-662.